新闻源 财富源

2019年11月12日 星期二

人福医药(600079)公告正文

人福医药:2012年半年度报告摘要

公告日期:2012-08-22

                                             武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                     武汉人福医药集团股份有限公司
                           2012 年半年度报告摘要§1 重要提示
    1.1 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    本半年度报告摘要摘自半年度报告全文,投资者欲了解详细内容,应当仔细阅读半年度报告全文。
    1.2 公司全体董事出席董事会会议。
    1.3 公司半年度财务报告未经审计。
    1.4 本公司不存在被控股股东及其关联方非经营性占用资金情况。
    1.5 本公司不存在违反规定决策程序对外提供担保的情况。
    1.6公司负责人王学海、主管会计工作负责人吴亚君及会计机构负责人(会计主管人员)何华琴声明:保证半年度报告中财务报告的真实、完整。§2 公司基本情况
    2.1 基本情况简介
       股票简称                                        人福医药
       股票代码                                          600079
    股票上市交易所                                   上海证券交易所
                                 董事会秘书                            证券事务代表
          姓名                       刘毅                                 吴文静
       联系地址        武汉市东湖高新区高新大道 666 号      武汉市东湖高新区高新大道 666 号
          电话                   027-87597232                          027-87597232
          传真                   027-87596393                          027-87596393
       电子信箱              renfu.pr@renfu.com.cn                wuwenjing@renfu.com.cn第 1 页 共 25 页
                                             武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
    2.2 主要财务数据和指标
    2.2.1 主要会计数据和财务指标
                                                                              单位:元 币种:人民币
                                                                            本报告期末比上年度
                               本报告期末             上年度期末
                                                                                期末增减(%)
    总资产                         6,629,820,668.96       6,170,360,101.07                      7.45
    所有者权益(或股东权益)       2,858,678,011.44       2,650,555,327.29                      7.85归属于上市公司股东的每
                                         5.7933                  5.3715                      7.85股净资产(元/股)
                                                                            本报告期比上年同期
                            报告期(1-6 月)           上年同期
                                                                                  增减(%)
    营业利润                        321,157,876.01          223,611,230.72                   43.62
    利润总额                        340,271,802.57          230,457,194.38                   47.65归属于上市公司股东的净
                                 201,309,707.81          140,525,061.41                     43.26利润归属于上市公司股东的扣
                                 160,254,228.26          140,269,308.75                     14.25除非经常性损益的净利润
    基本每股收益(元)                           0.41                   0.30                     36.67扣除非经常性损益后的基
                                            0.32                   0.30                      6.67本每股收益(元)
    稀释每股收益(元)                           0.41                   0.30                     36.67加权平均净资产收益率
                                            7.32                   6.95        增加 0.37 个百分点(%)经营活动产生的现金流量
                                  29,754,489.84         -120,480,361.64                   124.70净额每股经营活动产生的现金
                                         0.0603                 -0.2442                   124.69流量净额(元)
    2.2.2 非经常性损益项目
    √适用 □不适用
                                                                          单位:元 币种:人民币
               非经常性损益项目                                           金额
    非流动资产处置损益                                                                40,407,775.18计入当期损益的政府补助,但与公司正常经营业务密
    切相关,符合国家政策规定、按照一定标准定额或定                                     22,259,388.01量持续享受的政府补助除外
    除上述各项之外的其他营业外收入和支出                                               -2,421,977.62
    所得税影响额                                                                      -15,756,596.43
    少数股东权益影响额(税后)                                                         -3,433,109.59
                     合计                                                           41,055,479.55§3 股本变动及股东情况
    3.1 股份变动情况表第 2 页 共 25 页
                                                              武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
    √适用         □不适用
                                                                                                                     单位:股
                            本次变动前                        本次变动增减(+,-)                            本次变动后
                                      比例         发行     送    公积金                                                  比例
                          数量                                              其他           小计               数量
                                      (%)          新股     股      转股                                                  (%)一、有限售条件股
                        85,546,308      17.34                             -8,743,180     -8,743,180         76,803,128      15.56份1、国家持股2、国有法人持股
    3、其他内资持股        85,546,308      17.34                             -8,743,180     -8,743,180         76,803,128      15.56其中:境内非国有
                        63,688,358      12.91                                                               63,688,358      12.91法人持股
    境内自然人持
                        21,857,950          4.43                          -8,743,180     -8,743,180         13,114,770        2.65股4、外资持股其中:境外法人持股
    境外自然人持股二、无限售条件流
                     407,897,328        82.66                                8,743,180   8,743,180       416,640,508        84.44通股份
    1、人民币普通股     407,897,328        82.66                                8,743,180   8,743,180       416,640,508        84.442、境内上市的外资股3、境外上市的外资股4、其他
    三、股份总数        493,443,636            100                                     0              0     493,443,636          100
    3.2 股东数量和持股情况
                                                                                                                     单位:股
    报告期末股东总数                                                                                                        16,991 户
                                                     前十名股东持股情况
                                               持股比例                        持有有限售条件
      股东名称              股东性质                         持股总数                                  质押或冻结的股份数量
                                                 (%)                               股份数量
    武汉当代科技产业集         境内非国有
                                                   16.788       82,840,510           63,688,358        质押         82,840,000
    团股份有限公司                   法人中国工商银行股份有限公司-汇添富医药
                                     其他           1.877        9,259,822                     0       无                       0保健股票型证券投资基金中国光大银行股份有
    限公司-泰信先行策                  其他           1.824        9,000,000                     0       无                       0略开放式证券投资中国人寿保险(集团)
    公司-传统-普通保                  其他           1.761        8,688,880                     0       无                       0险产品中国建设银行-银华
    -道琼斯 88 精选证券                其他           1.677        8,274,504                     0       无                       0投资基金中国农业银行-长城
    安心回报混合型证券                  其他           1.623        8,009,832                     0       无                       0投资基金中国工商银行-汇添
                                     其他           1.611        7,949,760                     0       无                       0富均衡增长股票型证第 3 页 共 25 页
                                                   武汉人福医药集团股份有限公司二〇一二年半年度报告摘要券投资基金武汉高科国有控股集
                          国有法人         1.497       7,385,011                  0   质押      3,692,505团有限公司中国光大银行股份有限公司-摩根士丹利
                              其他         1.283       6,331,628                  0   无               0华鑫资源优选混合型证券投资基金中国工商银行-中银
    持续增长股票型证券           未知         1.244       6,137,045                  0   无               0投资基金
                                        前十名无限售条件股东持股情况
             股东名称                 持有无限售条件股份的数量                股份种类及数量武汉当代科技产业集团股份有限公
                                                      19,152,152   人民币普通股                19,152,152司中国工商银行股份有限公司-汇添
                                                       9,259,822   人民币普通股                 9,259,822富医药保健股票型证券投资基金中国光大银行股份有限公司-泰信
                                                       9,000,000   人民币普通股                 9,000,000先行策略开放式证券投资中国人寿保险(集团)公司-传统-普
                                                       8,688,880   人民币普通股                 8,688,880通保险产品中国建设银行-银华-道琼斯 88 精
                                                       8,274,504   人民币普通股                 8,274,504选证券投资基金中国农业银行-长城安心回报混合
                                                       8,009,832   人民币普通股                 8,009,832型证券投资基金中国工商银行-汇添富均衡增长股
                                                       7,949,760   人民币普通股                 7,949,760票型证券投资基金
    武汉高科国有控股集团有限公司                          7,385,011   人民币普通股                 7,385,011中国光大银行股份有限公司-摩根
    士丹利华鑫资源优选混合型证券投                        6,331,628   人民币普通股                 6,331,628资基金中国工商银行-中银持续增长股票
                                                       6,137,045   人民币普通股                 6,137,045型证券投资基金
                                     公司未知前十名股东之间、前十名无限售条件股东之间是否存在关联关系或上述股东关联关系或一致行动的说
                                     属于《上市公司股东持股变动信息披露管理办法》规定的一致行动人。公司明
                                     未知悉其他股东所持股份的质押、冻结情况。
    3.3 控股股东及实际控制人变更情况
    □适用 √不适用§4 董事、监事和高级管理人员情况
    4.1 董事、监事和高级管理人员持股变动
    □适用 √不适用§5 董事会报告
    5.1 主营业务分行业、产品情况表第 4 页 共 25 页
                                                          武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                                                                                单位:元 币种:人民币
                                                                      营业收入比      营业成本比
    分行业或分                                           营业利润率                                    营业利润率比上年
                    营业收入          营业成本                        上年同期增      上年同期增
    产品                                                 (%)                                         同期增减(%)
                                                                        减(%)         减(%)分行业
    医药          2,038,302,796.13    1,225,212,206.58           39.89          50.02          56.99    减少 2.67 个百分点
    房地产          207,734,927.74      109,304,591.82           47.38          19.54          39.47    减少 7.52 个百分点分产品
    药品          1,953,558,975.15    1,167,788,319.35           40.22          51.28          59.29    减少 3.01 个百分点
    安全套           84,743,820.98       57,423,887.23           32.24          25.74          21.36    增加 2.45 个百分点
    商品房          203,910,123.00      105,270,073.69           48.37          24.10          46.02    减少 7.75 个百分点
    5.2 主营业务分地区情况
                                                                                             单位:元 币种:人民币
             地区                            营业收入                            营业收入比上年增减(%)
    内销                                            2,239,524,739.04                                          43.54
    其中:东北                                         34,717,300.08                                           9.44
    华北                                              548,632,102.34                                          49.40
    华中                                            1,100,717,000.46                                          33.43
    华东                                              197,507,774.82                                          96.06
    西北                                              101,460,199.64                                          49.05
    西南                                              100,144,412.63                                          25.89
    华南                                              156,345,949.05                                          77.63
    出口                                               63,480,399.92                                         132.25
    合 计                                           2,303,005,138.96                                          45.06
    5.3 主营业务及其结构发生重大变化的原因说明
    □适用 √不适用
    5.4 主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明
    □适用 √不适用
    5.5 利润构成与上年度相比发生重大变化的原因分析
    □适用 √不适用
    5.6 募集资金使用情况
    5.6.1 募集资金运用
    √适用 □不适用
                                                                                              单位:万元 币种:人民币
                                 是否变                                          是否符合计               产生收益
         承诺项目                            拟投入金额       实际投入金额                     预计收益
                                 更项目                                            划进度                   情况宜昌人福药业有限责任公司
                                 否              13,242.78           13,303.51   是                         4459.53麻醉药注射制剂建设项目第 5 页 共 25 页
                                                武汉人福医药集团股份有限公司二〇一二年半年度报告摘要湖北葛店人福药业有限责任
    公司计生药制剂车间扩产项 是             5,007.50          4,423.76    是目武汉人福药业有限责任公司
                           否            8,059.00          8,134.33    是异地搬迁 GMP 改造项目武汉人福医药集团股份有限
                           否            8,042.96          8,048.00    是公司医药物流中心建设项目武汉人福医药集团股份有限
    公司医药工程研发中心及中 否             8,017.00          8,048.37    是试基地偿还银行贷款及补充公司流
                           否           13,630.61         13,630.61    是动资金
           合计               /         55,999.85         55,588.58             /                  /
    尚未使用的募集资金用途及去向                       存放在募集资金专户
    5.6.2 变更项目情况
    √适用 □不适用
                                            公司于 2011 年 3 月 25 日召开第六届董事会第五十次会议,根据
                                            《上海证券交易所上市公司募集资金管理规定》和公司《募集资
                                            金管理办法》的规定,审议并通过了《关于变 更部分募集资金投
                                            资项目实施主体及实施地点的预案》,决议将“计生药制剂车间
                                            扩产项目”的实施主体变更为武汉九珑人福药业有限责任公司,
    变更原因及变更程序说明(分具体项目)       项目实施地点由湖北葛店经济技术开发区人福医药工业园葛店
                                            人福原预留土地变更为武汉市东湖高新技术开发区光谷生物城
                                            九龙产业基地内。该事项已经 2011 年 4 月 22 日召开的公司 2010
                                            年年度股东大会审议通过。
    5.7 非募集资金项目情况
                                                                                    单位:元 币种:人民币
              项目名称                      项目金额                项目进度            项目收益情况
    增资 PuracapPharmaceuticalLLC                1,277,180.00      完成                  不适用增资天风证券股份有限公司(原:天
                                              88,400,000.00     完成                  不适用风证券有限责任公司)
    成立武汉九珑医药有限责任公司                 10,000,000.00     完成                  不适用成立湖北葛店人福药用辅料有限责
                                               8,500,000.00     完成                  不适用任公司收购北京玛诺生物制药有限公司
                                              13,250,000.00     完成                  不适用62.50%的股权
                合计                        121,427,180.00                  /                  /
    5.8 董事会下半年的经营计划修改计划
    □适用 √不适用
    5.9 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及说明第 6 页 共 25 页
                                                         武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
    □适用 √不适用
    5.10 公司董事会对会计师事务所本报告期“非标准审计报告”的说明
    □适用 √不适用
    5.11 公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明
    □适用 √不适用§6 重要事项
    6.1 收购资产
    √适用      □不适用
                                                                                             单位:万元 币种:人民币
                                                                    自本年初至本                   所涉及        所涉及
                                                     自购买日起                    是否为关
                                                                    期末为公司贡                   的资产        的债权
    交易对方或                                收购       至报告期末                    联交易(如
               被收购资产       购买日                              献的净利润(适                 产权是        债务是
    最终控制方                                价格       为公司贡献                    是,说明定
                                                                    用于同一控制                   否已全        否已全
                                                       的净利润                    价原则)
                                                                    下的企业合并)                 部过户        部转移
    康普拉斯     北京玛诺生物      2012 年
    (中国)控   制药有限公司      2 月 29   700.00           158.96                    否             是            是
    股有限公司   40%股权           日
             北京玛诺生物      2012 年玛诺科技亚
             制药有限公司      5 月 17   625.00            -0.69                    否             是            是洲有限公司
             22.5%股权         日
    6.2 出售资产
    √适用      □不适用
                                                                                             单位:万元 币种:人民币
                                                      本年初起至
                                                                                是否为关       所涉及的     所涉及的
                                                      出售日该出
                                                                    出售产生    联交易(如     资产产权     债权债务
    交易对方    被出售资产      出售日      出售价格     售资产为公
                                                                      的损益    是,说明定     是否已全     是否已全
                                                      司贡献的净
                                                                                价原则)         部过户       部转移
                                                          利润
             出售湖北南武汉当代
             湖当代学生
    科技产业                    2012 年 6
             公寓物业有                  14,274.00         -38.70       40.04   是 净资产     是            是
    集团股份                    月 12 日
             限公司有限公司
             98.46%股权
    6.3 担保事项
    √适用      □不适用第 7 页 共 25 页
                                                       武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                                                                      单位:万元 币种:人民币
                       公司对外担保情况(不包括对控股子公司的担保)
    报告期内担保发生额合计                                                                                    0
    报告期末担保余额合计                                                                                      0
                                 公司对控股子公司的担保情况
    报告期内对子公司担保发生额合计                                                                   45,850.00
    报告期末对子公司担保余额合计                                                                     72,160.00
                         公司担保总额情况(包括对控股子公司的担保)
    担保总额                                                                                         72,160.00
    担保总额占公司净资产的比例(%)                                                                        27.22其中:
    为股东、实际控制人及其关联方提供担保的金额                                                                0
    直接或间接为资产负债率超过 70%的被担保对象提供的债务担保金额                                             0
    担保总额超过净资产 50%部分的金额                                                                         0
    上述三项担保金额合计                                                                                      0
    6.4 关联债权债务往来
    □适用     √不适用
    6.5 重大诉讼仲裁事项
    □适用     √不适用
    6.6 其他重大事项及其影响和解决方案的分析说明
    6.6.1 证券投资情况
    □适用     √不适用
    6.6.2 持有其他上市公司股权情况
    □适用     √不适用
    6.6.3 持有非上市金融企业股权情况
    √适用     □不适用
                                            占该公                                  报告期所
    所持对象   最初投资成本                               期末账面价值      报告期损               会计核   股份来
                           持有数量(股)   司股权                                  有者权益
    名称         (元)                                     (元)        益(元)               算科目     源
                                            比例(%)                               变动(元)汉口银行
                                                                                               长期股
    股份有限    5,150,000.00     6,150,000.00      0.274     5,150,000.00        0.00       0.00            购买
                                                                                               权投资公司
    湖北银行                                                                                       长期股
           10,000,000.00    10,000,000.00       1.82    10,000,000.00        0.00       0.00            购买
    股份有限                                                                                       权投资第 8 页 共 25 页
                                                         武汉人福医药集团股份有限公司二〇一二年半年度报告摘要公司宜昌分行天风证券股份有限
    公司(原:                                                                                          长期股
           291,180,680.18    278,660,450.00   17.75      310,687,216.16   806,529.47   -99,807.16            购买
    天风证券                                                                                            权投资有限责任公司)武汉江夏
    民生村镇                                                                                            长期股
             4,000,000.00      4,000,000.00       5.00     4,000,000.00         0.00        0.00             出资
    银行股份                                                                                            权投资有限公司湖北竹溪
    农村商业                                                                                            长期股
             6,500,000.00      6,500,000.00       5.00     6,500,000.00   116,666.67        0.00             出资
    银行股份                                                                                            权投资有限公司
    合计     316,830,680.18    305,310,450.00   /          336,337,216.16   923,196.14   -99,807.16      /       /§7 财务会计报告
    7.1 审计意见
    财务报告                   √未经审计                               □审计
    7.2 财务报表第 9 页 共 25 页
                                                  武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                         合并资产负债表
    编制单位: 武汉人福医药集团股份有限公司        报告截止日:2012 年 6 月 30 日    单位:元       币种:人民币
                 项目                附注                 期末余额                    年初余额流动资产:
    货币资金                    五、(一)                    773,777,099.77              768,375,737.72
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                    五、(二)                     83,008,442.34               84,335,334.91
    应收账款                    五、(三)                  1,018,954,500.66              780,709,437.66
    预付款项                    五、(四)                    521,713,586.56              643,151,498.70
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息                                                                                 1,954,109.59
    应收股利
    其他应收款                  五、(五)                    339,019,103.68              297,272,731.91
    买入返售金融资产
    存货                        五、(六)                    944,740,924.91              930,323,969.17
    一年内到期的非流动资产
    其他流动资产
       流动资产合计                                          3,681,213,657.92             3,506,122,819.66非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                五、(八)                  1,048,972,364.29             1,146,538,691.39
    投资性房地产
    固定资产                    五、(九)                    829,168,933.08              691,043,206.18
    在建工程                    五、(十)                    340,751,547.45              274,265,433.87
    工程物资                    五、(十一)                   77,225,133.57               88,667,937.70
    固定资产清理                                                    7,567.67
    生产性生物资产
    油气资产
    无形资产                    五、(十二)                  433,407,296.42              284,672,075.95
    开发支出
    商誉                        五、(十三)                  206,771,873.86              166,994,785.80
    长期待摊费用                五、(十四)                    2,127,210.39                 1,580,569.32
    递延所得税资产              五、(十五)                   10,175,084.31               10,474,581.20
    其他非流动资产
       非流动资产合计                                        2,948,607,011.04             2,664,237,281.41
            资产总计                                         6,629,820,668.96             6,170,360,101.07第 10 页 共 25 页
                                                   武汉人福医药集团股份有限公司二〇一二年半年度报告摘要流动负债:
    短期借款                     五、(十八)               1,396,148,200.00              1,072,115,513.74
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                     五、(十九)                 75,170,283.00                 43,188,446.50
    应付账款                     五、(二十)                430,648,079.31                355,242,628.20
    预收款项                     五、(二十一)              254,744,045.72                465,332,865.48
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                 五、(二十二)                 6,501,646.06                  4,855,020.52
    应交税费                     五、(二十三)               67,964,048.82                 85,348,220.43
    应付利息                     五、(二十四)               17,083,133.56                 20,469,258.87
    应付股利                     五、(二十五)                 7,974,654.59                37,582,352.27
    其他应付款                   五、(二十六)              262,975,529.66                279,865,573.81
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    一年内到期的非流动负债       五、(二十七)              135,000,000.00
    其他流动负债                 五、(二十八)              400,000,000.00                400,000,000.00
       流动负债合计                                          3,054,209,620.72              2,763,999,879.82非流动负债:
    长期借款                     五、(二十九)              178,772,170.00                226,503,228.60
    应付债券
    长期应付款                   五、(三十)                                               12,272,728.00
    专项应付款                   五、(三十一)                 2,748,509.32                  1,002,570.54
    预计负债
    递延所得税负债
    其他非流动负债               五、(三十二)               39,590,549.59                 27,623,554.55
       非流动负债合计                                         221,111,228.91                267,402,081.69
         负债合计                                            3,275,320,849.63              3,031,401,961.51所有者权益(或股东权益):
    实收资本(或股本)           五、(三十三)              493,443,636.00                493,443,636.00
    资本公积                     五、(三十四)             1,139,157,461.16              1,131,426,972.13
    减:库存股
    专项储备
    盈余公积                     五、(三十五)              125,380,911.27                125,380,911.27
    一般风险准备
    未分配利润                   五、(三十六)             1,101,702,984.83               900,393,277.02
    外币报表折算差额                                           -1,006,981.82                    -89,469.13
    归属于母公司所有者权益合计                              2,858,678,011.44              2,650,555,327.29
    少数股东权益                                             495,821,807.89                488,402,812.27
         所有者权益合计                                      3,354,499,819.33              3,138,958,139.56
       负债和所有者权益总计                                  6,629,820,668.96              6,170,360,101.07
    法定代表人:王学海                主管会计工作负责人:吴亚君                    会计机构负责人:何华琴第 11 页 共 25 页
                                                      武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                         母公司资产负债表
    编制单位: 武汉人福医药集团股份有限公司             报告截止日:2012 年 6 月 30 日    单位:元      币种:人民币
                项目                        附注                期末余额                 年初余额流动资产:
    货币资金                                                      293,326,959.05          268,010,023.72
    交易性金融资产
    应收票据
    应收账款                            十二、(一)               29,968,607.15              12,020,997.26
    预付款项                                                       43,775,328.82              49,694,571.38
    应收利息
    应收股利                                                       20,917,617.02
    其他应收款                          十二、(二)              895,860,203.02          621,193,675.52
    存货                                                          196,489,190.65          230,289,250.86
    一年内到期的非流动资产
    其他流动资产
        流动资产合计                                             1,480,337,905.71        1,181,208,518.74非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                        十二、(三)            2,219,240,618.84        2,406,746,296.59
    投资性房地产
    固定资产                                                      124,800,213.80          125,853,694.05
    在建工程                                                         1,035,000.00
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                                          609,699.10                553,620.00
    开发支出
    商誉
    长期待摊费用
    递延所得税资产
    其他非流动资产
        非流动资产合计                                           2,345,685,531.74        2,533,153,610.64
            资产总计                                             3,826,023,437.45        3,714,362,129.38第 12 页 共 25 页
                                           武汉人福医药集团股份有限公司二〇一二年半年度报告摘要流动负债:
    短期借款                                         479,500,000.00            380,000,000.00
    交易性金融负债
    应付票据
    应付账款                                          44,438,611.33             44,180,971.19
    预收款项                                         137,015,138.00            336,429,512.02
    应付职工薪酬                                          576,996.37               443,338.51
    应交税费                                          24,430,718.69             12,249,019.20
    应付利息                                          15,600,000.00             17,600,000.00
    应付股利                                              341,740.32               341,740.32
    其他应付款                                        38,935,894.73             82,653,143.27
    一年内到期的非流动负债                            50,000,000.00
    其他流动负债                                     400,000,000.00            400,000,000.00
        流动负债合计                                1,190,839,099.44          1,273,897,724.51非流动负债:
    长期借款                                                                    50,000,000.00
    应付债券
    长期应付款
    专项应付款                                         2,286,552.71
    预计负债
    递延所得税负债
    其他非流动负债                                                                 500,000.00
        非流动负债合计                                  2,286,552.71             50,500,000.00
          负债合计                                  1,193,125,652.15          1,324,397,724.51所有者权益(或股东权益):
    实收资本(或股本)                               493,443,636.00            493,443,636.00
    资本公积                                       1,160,226,710.40          1,152,488,341.86
    减:库存股
    专项储备
    盈余公积                                         125,380,911.27            125,380,911.27
    一般风险准备
    未分配利润                                       853,846,527.63            618,651,515.74
    所有者权益(或股东权益)合计                       2,632,897,785.30          2,389,964,404.87
        负债和所有者权益(或股
                                                    3,826,023,437.45          3,714,362,129.38东权益)总计
    法定代表人:王学海            主管会计工作负责人:吴亚君           会计机构负责人:何华琴第 13 页 共 25 页
                                                    武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                             合并利润表
    编制单位: 武汉人福医药集团股份有限公司           2012 年 1-6 月        单位: 元          币种: 人民币
                    项目                         附注             本期金额               上期金额
    一、营业总收入                                                   2,303,005,138.96        1,587,588,643.83
    其中:营业收入                         五、(三十七)        2,303,005,138.96        1,587,588,643.83
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                                                   2,015,023,304.10        1,357,027,144.52
    其中:营业成本                         五、(三十七)        1,372,624,896.91         895,949,232.68
           利息支出
           手续费及佣金支出
           退保金
           赔付支出净额
           提取保险合同准备金净额
           保单红利支出
           分保费用
           营业税金及附加                   五、(三十八)           29,638,884.04          21,300,507.45
           销售费用                         五、(三十九)          376,953,684.88         263,413,219.99
           管理费用                         五、(四十)            170,257,257.34         129,086,639.64
           财务费用                         五、(四十一)           55,277,534.96          36,751,095.51
           资产减值损失                     五、(四十二)           10,271,045.97          10,526,449.25
    加:公允价值变动收益(损失以“-”号
    填列)投资收益(损失以“-”号填列)       五、(四十三)           33,176,041.15           -6,950,268.59
         其中:对联营企业和合营企业的投                              -9,436,173.36           -5,417,657.21资收益汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                                 321,157,876.01         223,611,230.72
    加:营业外收入                         五、(四十四)           22,659,828.87          12,377,598.23
    减:营业外支出                         五、(四十五)            3,545,902.31            5,531,634.57
       其中:非流动资产处置损失                                        594,571.31             1,668,520.29
    四、利润总额(亏损总额以“-”号填列)                             340,271,802.57         230,457,194.38
    减:所得税费用                         五、(四十六)           59,874,243.57          31,153,921.90
    五、净利润(净亏损以“-”号填列)                                 280,397,559.00         199,303,272.48
    归属于母公司所有者的净利润                                     201,309,707.81         140,525,061.41
    少数股东损益                                                    79,087,851.19          58,778,211.07六、每股收益:
    (一)基本每股收益                     五、(四十七)                    0.41                    0.30
    (二)稀释每股收益                     五、(四十七)                    0.41                    0.30
    七、其他综合收益                           五、(四十八)           -1,915,860.51              93,363.38
    八、综合收益总额                                                   278,481,698.49         199,396,635.86
    归属于母公司所有者的综合收益总额                               200,292,387.96         140,592,590.83
    归属于少数股东的综合收益总额                                    78,189,310.53          58,804,045.03
    法定代表人:王学海                主管会计工作负责人:吴亚君              会计机构负责人:何华琴第 14 页 共 25 页
                                                     武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                            母公司利润表
    编制单位: 武汉人福医药集团股份有限公司             2012 年 1-6 月              单位: 元      币种: 人民币
                     项目                     附注                  本期金额                上期金额
    一、营业收入                               十二、 四)               203,910,123.00           164,306,865.00
    减:营业成本                           十二、 四)               105,270,073.69            72,094,014.15
          营业税金及附加                                               14,811,171.74            11,989,284.23
          销售费用                                                      1,836,003.25               136,330.94
          管理费用                                                     29,165,690.02            18,462,856.48
          财务费用                                                     32,197,778.69            24,544,452.89
          资产减值损失                                                  2,897,752.86             2,256,044.10
    加:公允价值变动收益(损失以“-”号填列)
          投资收益(损失以“-”号填列)    十二、 五)               196,054,075.71            77,155,625.06
            其中:对联营企业和合营企业的
                                                                        -9,506,213.16            -4,955,484.02投资收益
    二、营业利润(亏损以“-”号填列)                                   213,785,728.46           111,979,507.27
    加:营业外收入                                                     7,897,900.00             2,663,000.00
    减:营业外支出                                                       287,431.49               300,000.00
          其中:非流动资产处置损失                                         37,431.49
    三、利润总额(亏损总额以“-”号填列)                               221,396,196.97           114,342,507.27
    减:所得税费用                                                    14,243,743.57
    四、净利润(净亏损以“-”号填列)                                   207,152,453.40           114,342,507.27五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益
    六、其他综合收益                                                         -91,927.65
    七、综合收益总额                                                     207,060,525.75           114,342,507.27
    法定代表人:王学海                    主管会计工作负责人:吴亚君                   会计机构负责人:何华琴第 15 页 共 25 页
                                                      武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                         合并现金流量表
    编制单位: 武汉人福医药集团股份有限公司              2012 年 1-6 月              单位: 元   币种: 人民币
                项目                         附注                    本期金额              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                                     2,299,430,763.17      1,521,171,619.19
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还                                                       1,185,020.11           222,157.28
    收到其他与经营活动有关的现金        五、(四十九)                178,490,245.05         84,188,007.86
       经营活动现金流入小计                                           2,479,106,028.33      1,605,581,784.33
    购买商品、接受劳务支付的现金                                     1,427,055,332.80      1,036,188,636.51
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现金                                    171,252,620.83        127,145,166.25
    支付的各项税费                                                    209,844,026.18        158,047,169.19
    支付其他与经营活动有关的现金        五、(四十九)                641,199,558.68        404,681,174.02
       经营活动现金流出小计                                           2,449,351,538.49      1,726,062,145.97
         经营活动产生的现金流量净额                                     29,754,489.84        -120,480,361.64二、投资活动产生的现金流量:
    收回投资收到的现金                                                   1,563,893.56          7,800,000.00
    取得投资收益收到的现金
    处置固定资产、无形资产和其他长期
                                                                           676,539.50         60,229,955.00资产收回的现金净额第 16 页 共 25 页
                                                    武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
      处置子公司及其他营业单位收到的
                                                                  193,448,033.61现金净额
      收到其他与投资活动有关的现金       五、(四十九)            21,926,353.98              2,596,731.88
        投资活动现金流入小计                                      217,614,820.65            70,626,686.88
      购建固定资产、无形资产和其他长期
                                                                  286,398,265.22           288,208,733.82资产支付的现金
      投资支付的现金                                               88,400,000.00           237,768,966.72
      质押贷款净增加额
      取得子公司及其他营业单位支付的
                                                                     8,083,554.13           30,573,660.45现金净额
      支付其他与投资活动有关的现金
        投资活动现金流出小计                                      382,881,819.35           556,551,360.99
          投资活动产生的现金流量净额                              -165,266,998.70         -485,924,674.11三、筹资活动产生的现金流量:
      吸收投资收到的现金                                           12,594,415.73           497,634,738.50
      其中:子公司吸收少数股东投资收到
                                                                   12,594,415.73            59,700,000.00的现金
      取得借款收到的现金                                          821,896,771.40           724,306,220.60
      发行债券收到的现金
      收到其他与筹资活动有关的现金                                475,000,000.00           400,000,000.00
        筹资活动现金流入小计                                     1,309,491,187.13         1,621,940,959.10
      偿还债务支付的现金                                          546,077,145.00           560,200,000.00
      分配股利、利润或偿付利息支付的现
                                                                  148,361,179.98            71,557,154.38金
      其中:子公司支付给少数股东的股
                                                                   83,642,757.43            19,007,780.27利、利润
      支付其他与筹资活动有关的现金       五、(四十九)           400,000,000.00               120,000.00
        筹资活动现金流出小计                                     1,094,438,324.98          631,877,154.38
          筹资活动产生的现金流量净额                              215,052,862.15           990,063,804.72
    四、汇率变动对现金及现金等价物的影响                                 861,008.76              -237,987.97
    五、现金及现金等价物净增加额                                      80,401,362.05           383,420,781.00
      加:期初现金及现金等价物余额                                693,375,737.72           466,419,192.31
    六、期末现金及现金等价物余额                                     773,777,099.77           849,839,973.31
    法定代表人:王学海                主管会计工作负责人:吴亚君                   会计机构负责人:何华琴第 17 页 共 25 页
                                                  武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                         母公司现金流量表
    编制单位: 武汉人福医药集团股份有限公司          2012 年 1-6 月         单位: 元        币种: 人民币
                      项目                        附注           本期金额              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                                  126,095,700.60         13,471,725.50
    收到的税费返还
    收到其他与经营活动有关的现金                                   81,118,837.33        114,619,243.81
       经营活动现金流入小计                                        207,214,537.93        128,090,969.31
    购买商品、接受劳务支付的现金                                   58,716,202.21         63,508,002.00
    支付给职工以及为职工支付的现金                                 12,501,922.41           6,324,057.80
    支付的各项税费                                                 17,878,921.11           3,091,387.85
    支付其他与经营活动有关的现金                                  409,828,181.89        234,965,292.19
       经营活动现金流出小计                                        498,925,227.62        307,888,739.84
          经营活动产生的现金流量净额                              -291,710,689.69       -179,797,770.53二、投资活动产生的现金流量:
    收回投资收到的现金                                              1,563,893.56           5,000,000.00
    取得投资收益收到的现金                                         27,497,256.15
    处置固定资产、无形资产和其他长期资产收回
                                                                        10,000.00的现金净额
    处置子公司及其他营业单位收到的现金净额                        333,810,000.00
    收到其他与投资活动有关的现金                                    2,750,449.36            636,126.97
       投资活动现金流入小计                                        365,631,599.07           5,636,126.97
    购建固定资产、无形资产和其他长期资产支付
                                                                    21,910,649.33         24,547,390.64的现金
    投资支付的现金                                                 88,400,000.00        220,556,000.00
    取得子公司及其他营业单位支付的现金净额                          1,277,180.00         75,610,000.00
    支付其他与投资活动有关的现金
       投资活动现金流出小计                                        111,587,829.33        320,713,390.64
          投资活动产生的现金流量净额                               254,043,769.74       -315,077,263.67三、筹资活动产生的现金流量:
    吸收投资收到的现金                                                                  437,934,738.50
    取得借款收到的现金                                            333,000,000.00        281,000,000.00
    发行债券收到的现金
    收到其他与筹资活动有关的现金                                  400,000,000.00        400,000,000.00
       筹资活动现金流入小计                                        733,000,000.00       1,118,934,738.50
    偿还债务支付的现金                                            233,500,000.00        295,500,000.00
    分配股利、利润或偿付利息支付的现金                             36,516,144.72         36,184,389.13
    支付其他与筹资活动有关的现金                                  400,000,000.00            120,000.00
       筹资活动现金流出小计                                        670,016,144.72        331,804,389.13
          筹资活动产生的现金流量净额                                62,983,855.28        787,130,349.37四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                                       25,316,935.33        292,255,315.17
    加:期初现金及现金等价物余额                                  268,010,023.72         95,459,511.42
    六、期末现金及现金等价物余额                                      293,326,959.05        387,714,826.59
    法定代表人:王学海               主管会计工作负责人:吴亚君                 会计机构负责人:何华琴第 18 页 共 25 页
                                                                                     武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                                                      合并所有者权益变动表
    编制单位:武汉人福医药集团股份有限公司                                          2012 年 1-6 月                                                     单位:元        币种:人民币
                                                                                               本期金额
                                                                     归属于母公司所有者权益
        项目
                                                                                                 一般                                    少数股东权益     所有者权益合计
                        实收资本(或股                      减:库    专项
                                           资本公积                             盈余公积         风险     未分配利润         其他
                            本)                            存股      储备
                                                                                                 准备
    一、上年年末余额       493,443,636.00   1,131,426,972.13                     125,380,911.27              900,393,277.02    -89,469.13   488,402,812.27      3,138,958,139.56
    加:会计政策变更
          前期差错更正
          其他
    二、本年年初余额       493,443,636.00   1,131,426,972.13                     125,380,911.27              900,393,277.02    -89,469.13   488,402,812.27      3,138,958,139.56三、本期增减变动金
    额(减少以“-”号填                        7,730,489.03                                                 201,309,707.81   -917,512.69     7,418,995.62       215,541,679.77列)
    (一)净利润                                                                                             201,309,707.81                  79,087,851.19       280,397,559.00
    (二)其他综合收益                            -99,807.16                                                                  -917,512.69      -898,540.66        -1,915,860.51上述(一)和(二)
                                               -99,807.16                                                 201,309,707.81   -917,512.69    78,189,310.53       278,481,698.49小计(三)所有者投入和
                                             7,830,296.19                                                                                -15,164,416.14         -7,334,119.95减少资本
    1.所有者投入资本                                                                                                                        12,594,200.00        12,594,200.002.股份支付计入所
                                             7,830,296.19                                                                                                        7,830,296.19有者权益的金额
    3.其他                                                                                                                                 -27,758,616.14        -27,758,616.14
    (四)利润分配                                                                                                                          -55,605,898.77        -55,605,898.771.提取盈余公积2.提取一般风险准备
    3.对所有者(或股                                                                                                                       -55,605,898.77        -55,605,898.77第 19 页 共 25 页
                                                                                     武汉人福医药集团股份有限公司二〇一二年半年度报告摘要东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额       493,443,636.00   1,139,157,461.16                     125,380,911.27             1,101,702,984.83     -1,006,981.82   495,821,807.89      3,354,499,819.33
                                                                                                                                                               单位:元 币种:人民币
                                                                                              上年同期金额
                                                                     归属于母公司所有者权益
        项目
                                                                                                 一般                                         少数股东权益        所有者权益合计
                        实收资本(或股                      减:库    专项
                                           资本公积                             盈余公积         风险        未分配利润          其他
                            本)                            存股      储备
                                                                                                 准备
    一、上年年末余额       471,585,686.00    736,723,525.92                      105,477,367.00                 638,806,046.96    -250,795.51    375,304,425.82      2,327,646,256.19
           加:会计政策变更
            前期差错更正
            其他
    二、本年年初余额       471,585,686.00    736,723,525.92                      105,477,367.00                 638,806,046.96    -250,795.51    375,304,425.82      2,327,646,256.19三、本期增减变动金
    额(减少以“-”号填    21,857,950.00    364,591,054.48                                                     121,661,633.97      67,529.42    129,970,428.16        638,148,596.03列)第 20 页 共 25 页
                                                                                武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
    (一)净利润                                                                                     140,525,061.41                  58,778,211.07    199,303,272.48
    (二)其他综合收益                                                                                                  67,529.42        25,833.96         93,363.38上述(一)和(二)
                                                                                                  140,525,061.41     67,529.42    58,804,045.03    199,396,635.86小计(三)所有者投入和
                          21,857,950.00    364,591,054.48                                                                        106,938,702.29    493,387,706.77减少资本
    1.所有者投入资本        21,857,950.00    415,836,788.50                                                                         79,288,500.00    516,983,238.502.股份支付计入所有
                                              2,323,530.03                                                                                            2,323,530.03者权益的金额
    3.其他                                    -53,569,264.05                                                                        27,650,202.29     -25,919,061.76
    (四)利润分配                                                                                   -18,863,427.44                 -35,772,319.16     -54,635,746.601.提取盈余公积2.提取一般风险准备3.对所有者(或股东)
                                                                                                  -18,863,427.44                 -35,772,319.16     -54,635,746.60的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额        493,443,636.00   1,101,314,580.40               105,477,367.00           760,467,680.93   -183,266.09   505,274,853.98   2,965,794,852.22
    法定代表人:王学海                                      主管会计工作负责人:吴亚君                                  会计机构负责人:何华琴第 21 页 共 25 页
                                                                                  武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                                               母公司所有者权益变动表
    编制单位:武汉人福医药集团股份有限公司                                       2012 年 1-6 月                                                    单位:元        币种:人民币
                                                                                                     本期金额
                 项目                   实收资本(或股                                                                    一般风险
                                                            资本公积         减:库存股   专项储备        盈余公积                   未分配利润          所有者权益合计
                                            本)                                                                            准备
    一、上年年末余额                       493,443,636.00    1,152,488,341.86                               125,380,911.27              618,651,515.74       2,389,964,404.87
    加:会计政策变更
          前期差错更正
          其他
    二、本年年初余额                        493,443,636.00   1,152,488,341.86                               125,380,911.27              618,651,515.74       2,389,964,404.87三、本期增减变动金额(减少以“-”号
                                                              7,738,368.54                                                           235,195,011.89        242,933,380.43填列)
    (一)净利润                                                                                                                        207,152,453.40        207,152,453.40
    (二)其他综合收益                                             -91,927.65                                                                                     -91,927.65
    上述(一)和(二)小计                                         -91,927.65                                                           207,152,453.40        207,060,525.75
    (三)所有者投入和减少资本                                   7,830,296.19                                                                                   7,830,296.191.所有者投入资本
    2.股份支付计入所有者权益的金额                              7,830,296.19                                                                                    7,830,296.193.其他(四)利润分配1.提取盈余公积2.提取一般风险准备3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用
    (七)其他                                                                                                                           28,042,558.49          28,042,558.49
    四、本期期末余额                        493,443,636.00   1,160,226,710.40                               125,380,911.27              853,846,527.63       2,632,897,785.30第 22 页 共 25 页
                                                                                 武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
                                                                                                                                            单位:元 币种:人民币
                                                                                               上年同期金额
                 项目                   实收资本(或股                                                                一般风险
                                                           资本公积         减:库存股   专项储备     盈余公积                   未分配利润       所有者权益合计
                                            本)                                                                        准备
    一、上年年末余额                       471,585,686.00    726,058,282.77                             105,477,367.00              459,056,913.87    1,762,178,249.64
    加:会计政策变更
          前期差错更正
          其他
    二、本年年初余额                       471,585,686.00    726,058,282.77                             105,477,367.00              459,056,913.87    1,762,178,249.64三、本期增减变动金额(减少以“-”号
                                         21,857,950.00    418,160,318.53                                                          95,479,079.83     535,497,348.36填列)
    (一)净利润                                                                                                                    114,342,507.27     114,342,507.27(二)其他综合收益
    上述(一)和(二)小计                                                                                                          114,342,507.27     114,342,507.27
    (三)所有者投入和减少资本              21,857,950.00    418,160,318.53                                                                            440,018,268.53
    1.所有者投入资本                       21,857,950.00    415,836,788.50                                                                            437,694,738.50
    2.股份支付计入所有者权益的金额                            2,323,530.03                                                                              2,323,530.033.其他
    (四)利润分配                                                                                                                  -18,863,427.44      -18,863,427.441.提取盈余公积2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                                                     -18,863,427.44      -18,863,427.444.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额                       493,443,636.00   1,144,218,601.30                            105,477,367.00              554,535,993.70    2,297,675,598.00
    法定代表人:王学海                                          主管会计工作负责人:吴亚君                                  会计机构负责人:何华琴第 23 页 共 25 页
                                         武汉人福医药集团股份有限公司二〇一二年半年度报告摘要
    7.3 本报告期无会计政策、会计估计的变更。
    7.4 本报告期无前期会计差错更正。
    7.5 企业合并及合并财务报表
    7.5.1 合并范围发生变更的说明
      (1)武汉九珑医药有限责任公司系子公司武汉九珑人福药业有限责任公司本期新设立的子公司,故新增合并其 2012 年 6 月 30 日资产负债表、2012 年上半年利润表和现金流量表;
      (2)湖北葛店人福药用辅料有限责任公司系子公司湖北省葛店人福药业有限责任公司本期新设立的子公司,故新增合并其 2012 年 6 月 30 日资产负债表、2012 年上半年利润表和现金流量表;
      (3)北京玛诺生物制药有限公司系子公司武汉人福昕和生物有限公司 2012 年度通过非同一控制下企业合并取得的子公司,故新增合并其 2012 年 6 月 30 日资产负债表、2012年 5 月 18 日-6 月 30 日利润表和现金流量表;
      (4)PuracapPharmaceuticalLLC 系公司 2012 年度通过非同一控制下企业合并取得的子公司,故新增合并其 2012 年 6 月 30 日资产负债表、2012 年 6 月 1 日-6 月 30 日利润表和现金流量表;
      (5)2012 年公司将持有的湖北南湖当代学生公寓物业有限公司全部股权转让给转让给武汉当代科技产业集团股份有限公司,并已收到全部股权转让款,故不再纳入合并报表范围。
    7.5.2本期新纳入合并范围的主体和本期不再纳入合并范围的主体
    7.5.2.1本期新纳入合并范围的子公司、特殊目的主体、通过受托经营或承租等方式形成控制权的经营实体
                                                                       单位:元 币种:人民币
                名称                   期末净资产                       本期净利润
    武汉九珑医药有限责任公司                        9,999,293.01                           -706.99
    湖北葛店人福药用辅料有限责任公司               10,000,000.00
    北京玛诺生物制药有限公司                         -447,117.84                        -16,615.79
    PuracapPharmaceuticalLLC                      -56,655,548.98                   -3,037,052.53
    7.5.2.2 本期不再纳入合并范围的子公司、特殊目的主体、通过受托经营或承租等方式第 24 页 共 25 页
                                                武汉人福医药集团股份有限公司二〇一二年半年度报告摘要形成控制权的经营实体
                                                                                 单位:元 币种:人民币
                    名称                            处置日净资产                期初至处置日净利润
    湖北南湖当代学生公寓物业有限公司                          144,566,404.40                    -387,048.99
    7.5.3 本期发生的非同一控制下企业合并
                                                                                 单位:元 币种:人民币
             被合并方               商誉金额                           商誉计算方法
                                                     企业合并成本大于合并中取得的被购买方可辨认净资产
                                                     公允价值份额的差额,应确认为商誉,若购买日无法取
    北京玛诺生物制药有限公司           15,868,596.81    得被购买方可辨认净资产公允价值,则以合并成本大于
                                                     合并中取得的被购买方账面净资产份额的差额确认为商
                                                     誉。
                                                     企业合并成本大于合并中取得的被购买方可辨认净资产
                                                     公允价值份额的差额,应确认为商誉,若购买日无法取
    PuracapPharmaceuticalLLC           23,908,491.25    得被购买方可辨认净资产公允价值,则以合并成本大于
                                                     合并中取得的被购买方账面净资产份额的差额确认为商
                                                     誉。
    7.5.4境外经营实体主要报表项目的折算汇率
      资产负债表中的资产和负债项目,采用资产负债表日的即期汇率:1 西非法郎=0.0122 人民币、1 美元=6.3249 人民币折算,所有者权益项目除"未分配利润"项目外,其他项目采用发生时的即期汇率折算,利润表中的收入和费用项目,按交易发生日即期汇率近似的汇率折算,折算产生的外币财务报表折算差额,在资产负债表中所有者权益项目下单独列示,现金流量按现金流量发生日即期汇率近似的汇率折算,汇率变动对现金的影响额,在现金流量表中单独列示。
                                                                   董事长:王学海
                                                         武汉人福医药集团股份有限公司董事会
                                                                            二〇一二年八月二十二日第 25 页 共 25 页